ArticleBMC cancer2026
Dosimetric superiority of proton radiosurgery in liver cancer: an in silico comparative dosimetric study.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThis in silico dosimetric study aimed to evaluate a potentially more efficient approach by assessing the dosimetric advantages of single-fraction 35 Gy proton radiosurgery relative to photon therapy.
methodsThis retrospective study included 98 patients with liver cancer who had undergone radiotherapy. Simulated treatment plans were generated for each patient to deliver a single fraction of 35 Gy using both photon and proton techniques. Patients were defined as eligible if all organs at risk (OARs) met the preset dose constraints. The Wilcoxon signed-rank test was applied to compare dosimetric parameters. The Youden index was used to identify the optimal cutoff for the safety margin between the OARs and the gross tumor volume.
resultsProton therapy demonstrated a higher overall compliance rate with dose constraints compared to photon therapy, with notable improvements for key OARs, including the liver (96.9% vs. 88.8%), duodenum (93.9% vs. 91.8%), and heart (91.8% vs. 89.8%). Proton therapy plans provided superior sparing of OARs by significantly reducing the maximum dose to all organs (p < 0.0001) and the optimal cutoff for satisfying dose constraints was generally < 1 cm. Furthermore, proton therapy significantly reduced the irradiated liver volume (V5Gy and V11.6 Gy, both p < 0.05), and this benefit was consistent across tumor sizes (≤ 3 cm or > 3 cm) and locations (dome, caudal, left medial, or central).
conclusionSingle-fraction 35 Gy proton radiosurgery offers enhanced sparing of OARs and a broader therapeutic window for patients with liver cancer compared with photon therapy from a dosimetric perspective. Whether these dosimetric benefits can translate into actual clinical efficacy requires prospective validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.